Setareh Seyedkazemi - 17 Jun 2025 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Signature
/s/ Aneta Fergson, Attorney-in-Fact
Issuer symbol
ADVM
Transactions as of
17 Jun 2025
Transactions value $
$0
Form type
4
Filing time
20 Jun 2025, 16:29:06 UTC
Previous filing
16 May 2025
Next filing
10 Dec 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Seyedkazemi Setareh CHIEF DEVELOPMENT OFFICER C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY /s/ Aneta Fergson, Attorney-in-Fact 20 Jun 2025 0001903088

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADVM Stock Option (Right to Buy) Disposed to Issuer $0 -42.5K -100% $0.00 0 17 Jun 2025 Common Stock 42.5K $17.30 Direct F1, F2, F3
transaction ADVM Stock Option (Right to Buy) Award $0 +42.5K $0.00 42.5K 17 Jun 2025 Common Stock 42.5K $10.14 Direct F1, F2, F3
transaction ADVM Stock Option (Right to Buy) Disposed to Issuer $0 -8.5K -100% $0.00 0 17 Jun 2025 Common Stock 8.5K $12.90 Direct F1, F4, F5
transaction ADVM Stock Option (Right to Buy) Award $0 +8.5K $0.00 8.5K 17 Jun 2025 Common Stock 8.5K $10.14 Direct F1, F4, F5
transaction ADVM Stock Option (Right to Buy) Disposed to Issuer $0 -40K -100% $0.00 0 10 Jun 2025 Common Stock 40K $19.90 Direct F1, F6, F7
transaction ADVM Stock Option (Right to Buy) Award $0 +40K $0.00 40K 17 Jun 2025 Common Stock 40K $10.14 Direct F1, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective March 21, 2024, the Issuer effected a reverse stock split (the "Reverse Split") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten.
F2 The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 6, 2022.
F3 Twenty-five percent (25%) of the total number of shares subject to the option vested and became exercisable on the first anniversary of January 6, 2022, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of January 6, 2026, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date.
F4 The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on March 8, 2022.
F5 The options vest in equal monthly installments over two years from August 16, 2023, such that all of the shares subject to the option shall become vested and exercisable as of August 16, 2025, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date.
F6 The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on February 12, 2024.
F7 Twenty-five percent (25%) of the total number of shares subject to the option vested and became exercisable on the first anniversary of February 12, 2024, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of February 12, 2028, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date.